Thomas O'Neil
Plus aucun poste en cours
Profil
Thomas P.
O'Neil worked as a Director of Financial Planning & Analysis at Monogram Biosciences, Inc., Vice President of Finance & Administration at Nodality, Inc. and ChemGenex Pharmaceuticals Pty Ltd., and Chief Financial & Accounting Officer at Protagonist Therapeutics, Inc. and Satsuma Pharmaceuticals, Inc. He also worked as a Principal at Autodesk, Inc., Nellcor, Inc., Miller Freeman, Inc., and Covidien LP, and as a CFO & Media Relations Contact at Sorbent Therapeutics, Inc. and Arcadia Biosciences, Inc. He received his undergraduate degree from Pomona College and his MBA from UCLA Anderson School of Management.
Anciens postes connus de Thomas O'Neil
| Sociétés | Poste | Fin |
|---|---|---|
| SATSUMA PHARMACEUTICALS, INC. | Director of Finance/CFO | 08/06/2023 |
| PROTAGONIST THERAPEUTICS, INC. | Director of Finance/CFO | 11/01/2019 |
| ARCADIA BIOSCIENCES, INC. | Director of Finance/CFO | 16/10/2015 |
Sorbent Therapeutics, Inc.
 Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA. | Director of Finance/CFO | 01/07/2014 |
ChemGenex Pharmaceuticals Pty Ltd.
 ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | Director of Finance/CFO | 01/08/2011 |
Formation de Thomas O'Neil
| Pomona College | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AUTODESK, INC. | Technology Services |
| ARCADIA BIOSCIENCES, INC. | Process Industries |
| PROTAGONIST THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Monogram Biosciences, Inc.
 Monogram Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Monogram Biosciences, Inc. develops and commercializes diagnostic products for the treatment of human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, and other viral illnesses, as well as cancer and other diseases. It offers HIV tests, including genotypic, phenotypic, tropism, and combined phenotype and genotype assays, suppression management and viral load testing, HCV assays and oncology tests. The company was founded in 1995 and is headquartered in South San Francisco, CA. | Commercial Services |
Sorbent Therapeutics, Inc.
Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Sorbent Therapeutics, Inc. develops therapies for cardiovascular and renal diseases. It focuses on the development of non-absorbed polymeric drugs to satisfy unmet clinical needs in large cardiovascular and renal markets such as heart failure, chronic kidney disease and hypertension. The company was founded by William R. Rajski, Dean Abrassart, Donald W. Joseph and Lee W. Henderson on January 25, 2005 and is headquartered in Sunnyvale, CA. | Health Technology |
Nodality, Inc.
 Nodality, Inc. BiotechnologyHealth Technology Nodality, Inc. develops bioinformatics tools to enhance drug development process. Its technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The company was founded by Michael C. Needels, Omar D. Perez, Garry P. Nolan and Rodney Weldon Turner in 2003 and is headquartered in San Francisco, CA. | Health Technology |
ChemGenex Pharmaceuticals Pty Ltd.
ChemGenex Pharmaceuticals Pty Ltd. Pharmaceuticals: MajorHealth Technology ChemGenex Pharmaceuticals Pty Ltd. develops pharmaceutical products. It develops small molecules with new mechanisms of action to treat malignancies with significant unmet medical needs. The firm also develops personalized oncology, obesity and diabetes medicines. The company was founded in September 1958 and is headquartered in Geelong, Australia. | Health Technology |
| Nellcor, Inc. | Health Technology |
Miller Freeman, Inc.
 Miller Freeman, Inc. Miscellaneous Commercial ServicesCommercial Services Founded in 1902, Miller Freeman, Inc. is a company that provides information and publication services. Part of Elliott International Advisors GP LLC, the company is based in San Francisco, CA. Miller Freeman was acquired by Nielsen BV from United News & Media Plc on July 18, 2000 for $638.98 million. | Commercial Services |
Covidien LP
 Covidien LP Medical SpecialtiesHealth Technology Covidien LP manufactures and distributes medical devices. Its products include disposable medical supplies, monitoring equipment, innovative wound closure products, advanced surgical devices, medical instruments and bulk analgesic pharmaceuticals. The company is headquartered in Mansfield, MA. | Health Technology |
HX Diagnostics, Inc.
 HX Diagnostics, Inc. Medical/Nursing ServicesHealth Services HX Diagnostics, Inc. provides diagnostic services for infectious diseases. It develops and commercializes seasonal and pandemic influenza assays that allow clinicians to make assessments of their patient's health status. The company was founded in 2006 and is headquartered in San Diego, CA. | Health Services |
| ASM Group, Inc. | |
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
